<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352974</url>
  </required_header>
  <id_info>
    <org_study_id>DIAGNODE-1</org_study_id>
    <nct_id>NCT02352974</nct_id>
  </id_info>
  <brief_title>GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)</brief_title>
  <acronym>DIAGNODE</acronym>
  <official_title>Open Label Pilot Trial in Adults With Recent-onset T1D to Evaluate the Safety, Diabetes Status and Immune Response of GAD-antigen (Diamyd®) Therapy Administered Into Lymph Nodes in Combination With an Oral Vitamin D Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnny Ludvigsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Child Diabetes Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ostergotland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diamyd Medical AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the main study is to:

        -  Evaluate the safety of giving GAD-Alum (Glutamic acid decarboxylase) (Diamyd) directly
           into lymph glands in combination with an oral vitamin D regimen

        -  Evaluate how the above mentioned treatments influence the immune system and endogenous
           insulin secretion.

      The objective of the sub-study is to:

        -  Evaluate safety after a fourth injection with 4 μg GAD-Alum direct into an inguinal
           lymph gland in 3 adult patients from the main study

        -  Evaluate how the above mentioned treatment influences the immune system and endogenous
           insulin secretion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be treated with 4 µg GAD-Alum into an inguinal lymph gland at three
      occasions, with one month intervals in combination with Vitamin D (14 000 IU/week) for 4
      months, starting 1 month prior to first GAD-Alum injection.

      A sub-study will include three adult patients from the main study and evaluate safety after a
      fourth injection with 4 μg GAD-Alum into an inguinal lymph gland in combination with oral
      vitamin D intake. The Prolonged Extension Study Period is 12 months and will start 30,5
      months after baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Injection Site Reactions Month 1</measure>
    <time_frame>Month 1</time_frame>
    <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Injection Site Reactions Month 2</measure>
    <time_frame>Month 2</time_frame>
    <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Injection Site Reactions Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Injection Site Reactions Month 32</measure>
    <time_frame>Month 32, extension period</time_frame>
    <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in C-peptide AUC (Area Under the Curve) (Mean 120min) Value, Month 15</measure>
    <time_frame>Baseline to month 15 at 0, 30, 60, 90, 120 minutes post-dose</time_frame>
    <description>Change from baseline to month 15 in C-peptide AUC (Area Under the Curve) (mean 120min) value
AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in C-peptide AUC(Mean 120min) Value, Month 30</measure>
    <time_frame>Baseline to month 30 at 0, 30, 60, 90, 120 minutes post-dose</time_frame>
    <description>Change from baseline to month 30 in C-peptide AUC(mean 120min) value
AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in C-peptide AUC(Mean 120min) Value, Month 43</measure>
    <time_frame>Baseline to month 43, extension period at 0, 30, 60, 90, 120 minutes post-dose</time_frame>
    <description>Change from baseline to month 43 in C-peptide AUC(mean 120min) value
AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in C-peptide 90-minute Value, Month 15</measure>
    <time_frame>Baseline to month 15</time_frame>
    <description>Change from baseline to month 15 in C-peptide 90-minute value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in C-peptide 90-minute Value, Month 30</measure>
    <time_frame>Baseline to month 30</time_frame>
    <description>Change from baseline to month 30 in C-peptide 90-minute value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in C-peptide 90-minute Value, Month 43</measure>
    <time_frame>Baseline to month 43, extension period</time_frame>
    <description>Change from baseline to month 43 in C-peptide 90-minute value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Fasting C-peptide Value, Month 15</measure>
    <time_frame>Baseline to month 15</time_frame>
    <description>Change from baseline to month 15 in fasting C-peptide value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Fasting C-peptide Value, Month 30</measure>
    <time_frame>Baseline to month 30</time_frame>
    <description>Change from baseline to month 30 in fasting C-peptide value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Fasting C-peptide Value, Month 43</measure>
    <time_frame>Baseline to month 43, extension period</time_frame>
    <description>Change from baseline to month 43 in fasting C-peptide value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in HbA1c, Month 15</measure>
    <time_frame>Baseline to month 15</time_frame>
    <description>Change from baseline to month 15 in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in HbA1c, Month 30</measure>
    <time_frame>Baseline to month 30</time_frame>
    <description>Change from baseline to month 30 in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in HbA1c, Month 43</measure>
    <time_frame>Baseline to month 43, extension period</time_frame>
    <description>Change from baseline to month 43 in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>External Insulin Dose, Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>External insulin dose at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>External Insulin Dose, Month 15</measure>
    <time_frame>Month 15</time_frame>
    <description>External insulin dose at month 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>External Insulin Dose, Month 30</measure>
    <time_frame>Month 30</time_frame>
    <description>External insulin dose at month 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>External Insulin Dose, Month 43</measure>
    <time_frame>Month 43, extension period</time_frame>
    <description>External insulin dose at month 43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean IDAA1c Values, Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean IDAA1c Values, Month 15</measure>
    <time_frame>Month 15</time_frame>
    <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean IDAA1c Values, Month 30</measure>
    <time_frame>Month 30</time_frame>
    <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean IDAA1c Values, Month 43</measure>
    <time_frame>Month 43, extension period</time_frame>
    <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>GAD-Alum+Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GAD-Alum</intervention_name>
    <arm_group_label>GAD-Alum+Vitamin D</arm_group_label>
    <other_name>Diamyd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>GAD-Alum+Vitamin D</arm_group_label>
    <other_name>Calciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent given by patients

          2. Type 1 diabetes according to the ADA (American Diabetes Association) classification
             with &lt; 6 months diabetes duration

          3. Age 12.00-29.99 years at diagnosis of Type 1 diabetes

          4. Fasting C-peptide ≥0.12 nmol/L

          5. Pos GADA(Antibodies to GAD with molecular mass 65,000) but &lt; 50 000 random units

          6. Females must agree to avoid pregnancy and have a negative urine pregnancy test

          7. Patients of childbearing potential must agree to using adequate contraception, until 1
             year after the last administration of GAD-Alum.

        Exclusion Criteria:

          1. Previous or current treatment with immunosuppressant therapy (although topical or
             inhaled steroids are accepted)

          2. Continuous treatment with any inflammatory drug (sporadic treatment e.g. because of
             headache or in connection with fever a few days will be accepted)

          3. Treatment with any oral or injected anti-diabetic medications other than insulin

          4. Treatment with Vitamin D, marketed or not, or unwilling to abstain from such
             medication during the trial

          5. A history of anaemia or significantly abnormal haematology results at screening

          6. A history of epilepsy, head trauma or cerebro-vascular accident, or clinical features
             of continuous motor unit activity in proximal muscles

          7. Clinically significant history of acute reaction to vaccines or other drugs in the
             past

          8. Treatment with any vaccine, including influenza vaccine, within 4 months prior to
             planned first study drug dose or planned treatment with any vaccine up to 4 months
             after the last injection with study drug.

          9. Participation in other clinical trials with a new chemical entity within the previous
             3 months

         10. Inability or unwillingness to comply with the provisions of this protocol

         11. A history of alcohol or drug abuse

         12. A significant illness other than diabetes within 2 weeks prior to first dosing

         13. Known human immunodeficiency virus (HIV) or hepatitis

         14. Females who are lactating or pregnant (the possibility of pregnancy must be excluded
             by urine βHCG (beta-human chorionic gonadotropin) on-site within 24 hours prior to the
             GAD-Alum treatment)

         15. Males or females not willing to use adequate contraception until 1 year after the last
             GAD-Alum treatment

         16. Presence of associated serious disease or condition, including active skin infections
             that preclude subcutaneous injection, which in the opinion of the investigator makes
             the patient non-eligible for the study

         17. Deemed by the investigator not being able to follow instructions and/or follow the
             study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnny Ludvigsson, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linkoeping University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linköping University</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <results_first_submitted>March 23, 2020</results_first_submitted>
  <results_first_submitted_qc>April 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2020</results_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Johnny Ludvigsson</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>Diamyd</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Juvenile Diabetes</keyword>
  <keyword>Diabetes Type 1</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Autoimmune Diabetes</keyword>
  <keyword>Insulin Dependent Diabetes</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>rhGAD65 (Recombinant Human GAD with molecular mass 65,000)</keyword>
  <keyword>GAD65</keyword>
  <keyword>GAD-Alum</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes mellitus Type 1</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02352974/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GAD-Alum+Vitamin D</title>
          <description>GAD(Glutamic acid decarboxylase)-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">Only 3 out of the 12 patients who completed the main study continued in to the extension period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GAD-Alum+Vitamin D</title>
          <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.8" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 1 diabetes duration</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GADA (Antibodies to GAD with molecular mass 65,000)</title>
          <units>U/mL^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4067.1" spread="8491.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weighted C-peptide</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.55" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>90-minute C-peptide</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.67" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting C-peptide</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.27" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.17" spread="28.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average insulin dose/kg/24 h</title>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.40" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IDAA1c</title>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.91" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Injection Site Reactions Month 1</title>
        <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
        <time_frame>Month 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Injection Site Reactions Month 1</title>
          <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oedema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Injection Site Reactions Month 2</title>
        <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
        <time_frame>Month 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Injection Site Reactions Month 2</title>
          <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oedema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Injection Site Reactions Month 3</title>
        <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
        <time_frame>Month 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Injection Site Reactions Month 3</title>
          <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oedema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Injection Site Reactions Month 32</title>
        <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
        <time_frame>Month 32, extension period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Injection Site Reactions Month 32</title>
          <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oedema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in C-peptide AUC (Area Under the Curve) (Mean 120min) Value, Month 15</title>
        <description>Change from baseline to month 15 in C-peptide AUC (Area Under the Curve) (mean 120min) value
AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration</description>
        <time_frame>Baseline to month 15 at 0, 30, 60, 90, 120 minutes post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in C-peptide AUC (Area Under the Curve) (Mean 120min) Value, Month 15</title>
          <description>Change from baseline to month 15 in C-peptide AUC (Area Under the Curve) (mean 120min) value
AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in C-peptide AUC(Mean 120min) Value, Month 30</title>
        <description>Change from baseline to month 30 in C-peptide AUC(mean 120min) value
AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration</description>
        <time_frame>Baseline to month 30 at 0, 30, 60, 90, 120 minutes post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in C-peptide AUC(Mean 120min) Value, Month 30</title>
          <description>Change from baseline to month 30 in C-peptide AUC(mean 120min) value
AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in C-peptide AUC(Mean 120min) Value, Month 43</title>
        <description>Change from baseline to month 43 in C-peptide AUC(mean 120min) value
AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration</description>
        <time_frame>Baseline to month 43, extension period at 0, 30, 60, 90, 120 minutes post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in C-peptide AUC(Mean 120min) Value, Month 43</title>
          <description>Change from baseline to month 43 in C-peptide AUC(mean 120min) value
AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in C-peptide 90-minute Value, Month 15</title>
        <description>Change from baseline to month 15 in C-peptide 90-minute value</description>
        <time_frame>Baseline to month 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in C-peptide 90-minute Value, Month 15</title>
          <description>Change from baseline to month 15 in C-peptide 90-minute value</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in C-peptide 90-minute Value, Month 30</title>
        <description>Change from baseline to month 30 in C-peptide 90-minute value</description>
        <time_frame>Baseline to month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in C-peptide 90-minute Value, Month 30</title>
          <description>Change from baseline to month 30 in C-peptide 90-minute value</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in C-peptide 90-minute Value, Month 43</title>
        <description>Change from baseline to month 43 in C-peptide 90-minute value</description>
        <time_frame>Baseline to month 43, extension period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in C-peptide 90-minute Value, Month 43</title>
          <description>Change from baseline to month 43 in C-peptide 90-minute value</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Fasting C-peptide Value, Month 15</title>
        <description>Change from baseline to month 15 in fasting C-peptide value</description>
        <time_frame>Baseline to month 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Fasting C-peptide Value, Month 15</title>
          <description>Change from baseline to month 15 in fasting C-peptide value</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Fasting C-peptide Value, Month 30</title>
        <description>Change from baseline to month 30 in fasting C-peptide value</description>
        <time_frame>Baseline to month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Fasting C-peptide Value, Month 30</title>
          <description>Change from baseline to month 30 in fasting C-peptide value</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Fasting C-peptide Value, Month 43</title>
        <description>Change from baseline to month 43 in fasting C-peptide value</description>
        <time_frame>Baseline to month 43, extension period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Fasting C-peptide Value, Month 43</title>
          <description>Change from baseline to month 43 in fasting C-peptide value</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in HbA1c, Month 15</title>
        <description>Change from baseline to month 15 in HbA1c</description>
        <time_frame>Baseline to month 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HbA1c, Month 15</title>
          <description>Change from baseline to month 15 in HbA1c</description>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.25" spread="18.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in HbA1c, Month 30</title>
        <description>Change from baseline to month 30 in HbA1c</description>
        <time_frame>Baseline to month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HbA1c, Month 30</title>
          <description>Change from baseline to month 30 in HbA1c</description>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.67" spread="18.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in HbA1c, Month 43</title>
        <description>Change from baseline to month 43 in HbA1c</description>
        <time_frame>Baseline to month 43, extension period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HbA1c, Month 43</title>
          <description>Change from baseline to month 43 in HbA1c</description>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.67" spread="21.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>External Insulin Dose, Baseline</title>
        <description>External insulin dose at baseline</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>External Insulin Dose, Baseline</title>
          <description>External insulin dose at baseline</description>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>External Insulin Dose, Month 15</title>
        <description>External insulin dose at month 15</description>
        <time_frame>Month 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>External Insulin Dose, Month 15</title>
          <description>External insulin dose at month 15</description>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>External Insulin Dose, Month 30</title>
        <description>External insulin dose at month 30</description>
        <time_frame>Month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>External Insulin Dose, Month 30</title>
          <description>External insulin dose at month 30</description>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>External Insulin Dose, Month 43</title>
        <description>External insulin dose at month 43</description>
        <time_frame>Month 43, extension period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>External Insulin Dose, Month 43</title>
          <description>External insulin dose at month 43</description>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean IDAA1c Values, Baseline</title>
        <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean IDAA1c Values, Baseline</title>
          <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean IDAA1c Values, Month 15</title>
        <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
        <time_frame>Month 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean IDAA1c Values, Month 15</title>
          <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.64" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean IDAA1c Values, Month 30</title>
        <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
        <time_frame>Month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean IDAA1c Values, Month 30</title>
          <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.36" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean IDAA1c Values, Month 43</title>
        <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
        <time_frame>Month 43, extension period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GAD-Alum+Vitamin D</title>
            <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Mean IDAA1c Values, Month 43</title>
          <description>Insulin dose-adjusted HbA1c (IDAA1c)</description>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.11" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During main study period (baseline to month 30) and extension (month 37 and 43)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GAD-Alum+Vitamin D</title>
          <description>GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days
GAD-Alum
Vitamin D</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Plantar fascilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Autism spectrum disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Åsa Carlsheimer</name_or_title>
      <organization>4Pharma AB</organization>
      <phone>+4672244516</phone>
      <email>asa.carlsheimer@4pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

